ES3007339T3 - Cladribine regimen for treating multiple sclerosis - Google Patents

Cladribine regimen for treating multiple sclerosis Download PDF

Info

Publication number
ES3007339T3
ES3007339T3 ES22166610T ES22166610T ES3007339T3 ES 3007339 T3 ES3007339 T3 ES 3007339T3 ES 22166610 T ES22166610 T ES 22166610T ES 22166610 T ES22166610 T ES 22166610T ES 3007339 T3 ES3007339 T3 ES 3007339T3
Authority
ES
Spain
Prior art keywords
cladribine
months
pharmaceutical formulation
administered
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES22166610T
Other languages
English (en)
Spanish (es)
Inventor
Luca Giampiero De
Arnaud Ythier
Alain Munafo
Maria Lopez-Bresnahan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3007339(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono SA filed Critical Merck Serono SA
Application granted granted Critical
Publication of ES3007339T3 publication Critical patent/ES3007339T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES22166610T 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis Expired - Lifetime ES3007339T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22

Publications (1)

Publication Number Publication Date
ES3007339T3 true ES3007339T3 (en) 2025-03-19

Family

ID=36227798

Family Applications (2)

Application Number Title Priority Date Filing Date
ES22166610T Expired - Lifetime ES3007339T3 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis
ES18151634T Expired - Lifetime ES2921858T3 (es) 2004-12-22 2005-12-20 Régimen de cladribina en el tratamiento de la esclerosis múltiple

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES18151634T Expired - Lifetime ES2921858T3 (es) 2004-12-22 2005-12-20 Régimen de cladribina en el tratamiento de la esclerosis múltiple

Country Status (25)

Country Link
US (2) US7713947B2 (https=)
EP (7) EP3332789B1 (https=)
JP (7) JP5795456B2 (https=)
KR (1) KR20070091662A (https=)
AR (1) AR052830A1 (https=)
AU (2) AU2005318190B2 (https=)
BR (1) BRPI0517132B8 (https=)
CA (2) CA3087419C (https=)
CY (3) CY1112614T1 (https=)
DK (3) DK3332789T3 (https=)
EA (1) EA015799B1 (https=)
ES (2) ES3007339T3 (https=)
FI (1) FI4070800T3 (https=)
FR (1) FR18C1008I2 (https=)
HR (1) HRP20120228T1 (https=)
HU (3) HUE059133T2 (https=)
IL (2) IL183930A0 (https=)
LT (3) LT3332789T (https=)
LU (1) LUC00064I2 (https=)
MX (1) MX2007007610A (https=)
NO (1) NO20073813L (https=)
PL (4) PL3332789T3 (https=)
SG (1) SG160391A1 (https=)
SI (3) SI4070800T1 (https=)
WO (1) WO2006067141A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3332789B1 (en) 2004-12-22 2022-04-06 Merck Serono SA Cladribine regimen for treating multiple sclerosis
AU2007253254B2 (en) * 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2011117267A1 (en) 2010-03-24 2011-09-29 Merck Serono Sa Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
EP3713582A1 (en) * 2017-11-24 2020-09-30 Merck Patent GmbH Cladribine regimen for use intreating progressive forms of multiple sclerosis
CA3194812A1 (en) 2020-09-10 2022-03-17 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
ES2182920T3 (es) 1994-12-22 2003-03-16 Ortho Pharma Corp Formulaciones solubles de 2-cloro02'-deoxiadenosina.
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
ES2405825T3 (es) 2002-09-25 2013-06-03 Brigham Young University Método para la preparación de compuestos 2-halo-2'-desoxiadenosina a partir de 2'-desoxiguanosina
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
AU2004216485B2 (en) * 2003-02-25 2009-06-11 Merck Serono Sa Combined use of ribavirin and interferon beta in demyelinating diseases
HRP20050924A2 (en) 2003-03-28 2006-08-31 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
ES2409884T3 (es) * 2003-03-28 2013-06-28 Ares Trading S.A. Formulaciones orales de cladribina
EP3332789B1 (en) 2004-12-22 2022-04-06 Merck Serono SA Cladribine regimen for treating multiple sclerosis
AU2007253254B2 (en) * 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis

Also Published As

Publication number Publication date
LT3332789T (lt) 2022-07-25
CA3087419C (en) 2023-03-07
LTPA2018503I1 (lt) 2018-03-12
ES2921858T3 (es) 2022-09-01
EP2275110B1 (en) 2013-07-10
EA015799B1 (ru) 2011-12-30
EP4070800A1 (en) 2022-10-12
EP2805723B1 (en) 2018-01-17
EP2263678A2 (en) 2010-12-22
LTC2805723I2 (lt) 2022-04-25
BRPI0517132A (pt) 2008-09-30
FR18C1008I1 (https=) 2018-03-30
IL212421A (en) 2014-01-30
CA3087419A1 (en) 2006-06-29
EP3332789B1 (en) 2022-04-06
SG160391A1 (en) 2010-04-29
BRPI0517132B1 (pt) 2020-02-18
WO2006067141A1 (en) 2006-06-29
LT4070800T (lt) 2025-01-10
PL3332789T3 (pl) 2022-08-22
JP2015180685A (ja) 2015-10-15
JP6290962B2 (ja) 2018-03-07
JP6092945B2 (ja) 2017-03-08
DK3332789T3 (da) 2022-07-11
DK4070800T3 (da) 2025-01-02
JP2020193206A (ja) 2020-12-03
HRP20120228T1 (hr) 2012-04-30
KR20070091662A (ko) 2007-09-11
SI4070800T1 (sl) 2025-03-31
AR052830A1 (es) 2007-04-04
HUE070333T2 (hu) 2025-05-28
AU2011200768B2 (en) 2012-09-13
IL212421A0 (en) 2011-06-30
SI2805723T1 (en) 2018-02-28
JP5908863B2 (ja) 2016-04-26
US20090081163A1 (en) 2009-03-26
FI4070800T3 (fi) 2025-01-14
PL1827461T3 (pl) 2012-07-31
SI3332789T1 (sl) 2022-08-31
MX2007007610A (es) 2007-08-03
EA200701221A1 (ru) 2008-02-28
US8377903B2 (en) 2013-02-19
EP3332789A1 (en) 2018-06-13
EP2263678B1 (en) 2014-06-11
CY1112614T1 (el) 2016-02-10
AU2011200768A1 (en) 2011-03-17
JP2013216664A (ja) 2013-10-24
AU2005318190B2 (en) 2010-11-25
EP2805723A1 (en) 2014-11-26
PL2805723T3 (pl) 2018-04-30
EP4523753A2 (en) 2025-03-19
CA2588966A1 (en) 2006-06-29
FR18C1008I2 (fr) 2019-03-01
JP5795456B2 (ja) 2015-10-14
HUS1800009I1 (hu) 2018-05-02
IL183930A0 (en) 2007-10-31
EP4523753A3 (en) 2025-05-28
HUE059133T2 (hu) 2022-10-28
EP2275110A3 (en) 2011-04-27
CY2018006I2 (el) 2018-06-27
JP2008524313A (ja) 2008-07-10
CY2018006I1 (el) 2018-06-27
PL4070800T3 (pl) 2025-03-10
CA2588966C (en) 2020-07-21
JP2017101061A (ja) 2017-06-08
EP1827461A1 (en) 2007-09-05
CY1119790T1 (el) 2018-06-27
AU2005318190A1 (en) 2006-06-29
LUC00064I2 (https=) 2018-03-28
EP2263678A3 (en) 2011-04-27
DK2805723T3 (da) 2018-01-29
US20100203017A1 (en) 2010-08-12
JP2018165271A (ja) 2018-10-25
LUC00064I1 (https=) 2018-02-14
JP6430554B2 (ja) 2018-11-28
JP2016138128A (ja) 2016-08-04
US7713947B2 (en) 2010-05-11
BRPI0517132B8 (pt) 2021-05-25
NO20073813L (no) 2007-09-21
EP4070800B1 (en) 2024-10-16
EP2275110A2 (en) 2011-01-19
EP1827461B1 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
US8377903B2 (en) Cladribine regimen for treating multiple sclerosis
ES2666146T3 (es) Régimen con cladribina para tratar la esclerosis múltiple
HK40083827B (en) Cladribine regimen for treating multiple sclerosis
HK40083827A (en) Cladribine regimen for treating multiple sclerosis
CN101090726A (zh) 治疗多发性硬化的克拉屈滨方案